M
Mayur D. Mody
Researcher at Emory University
Publications - 11
Citations - 117
Mayur D. Mody is an academic researcher from Emory University. The author has contributed to research in topics: Head and neck cancer & Cancer. The author has an hindex of 5, co-authored 9 publications receiving 75 citations. Previous affiliations of Mayur D. Mody include Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy
Nabil F. Saba,Mayur D. Mody,Elaine S. Tan,Harpaul S. Gill,Alessandra Rinaldo,Robert P. Takes,Primož Strojan,Dana M. Hartl,Dana M. Hartl,Jan B. Vermorken,Missak Haigentz,Alfio Ferlito +11 more
TL;DR: An overview of the toxicity profile of the different systemic agents is provided and a perspective into the future of SCCHN treatment is provided.
Journal ArticleDOI
Systemic therapy in non-conventional cancers of the larynx.
TL;DR: This manuscript provides a detailed and comprehensive overview of systemic therapy considerations for the following histologic tumor types of the larynx: verrucous carcinoma, HPV-related SCC, basaloid SCC (BSCC), lymphoepithelial carcinoma (LEC), adenosquamous carcinomas (ASC), typical and atypical carcinoid
Journal ArticleDOI
Multimodal Therapy for Sinonasal Malignancies: Updates and Review of Current Treatment.
Mayur D. Mody,Nabil F. Saba +1 more
TL;DR: Non-surgical approaches such as novel radiation approaches as well as intensification with systemic therapy hold promise in altering the organ preservation rate as wellAs overall survival for patients.
Journal ArticleDOI
The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review.
TL;DR: An overview of the evidence thus far supporting the use of taxanes in the concurrent, induction, and adjuvant settings, as well as their use in the treatment of recurrent or metastatic SCCHN, and an analytical discussion of the projected future role of taxane in the management ofSCCHN.
Journal ArticleDOI
Parenteral Bevacizumab for the Treatment of Severe Respiratory Papillomatosis in an Adult Population.
Andrew Tkaczuk,Sumita Trivedi,Mayur D. Mody,Conor E. Steuer,Dong M. Shin,Adam M. Klein,Nabil F. Saba +6 more
TL;DR: The safety and efficacy of utilizing parenteral bevacizumab in the management of severe RRP in adults in adults is examined.